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Abstract Background Previous studies have suggest ed that hyperhomocysteinemia may be a risk factor for venous thrombosis. To assess the risk of venous throm bosis associated with hyperhomocysteinemia, we stud ied plasma homocysteine levels in patients with a first episode of deep-vein thrombosis and in normal control subjects.
Methods. We measured plasma homocysteine levels in 269 patients with a first, objectively diagnosed epi sode of deep-vein thrombosis and in 269 healthy con trols matched to the patients according to age and sex. Hyperhomocysteinemia was defined as a plasma ho mocysteine level above the 95th percentile in the control group (18.5 /xmol per liter).
Results. Of the 269 patients, 28 (10 percent) had plas ma homocysteine levels above the 95th percentile for the controls, as compared with 13 of the controls (matched odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.2). The association between elevated homocysteine levels and venous thrombosis was stronger among women than among men and increased with age. The exclusion of subjects with other established risk factors for thrombosis (e.g., a deficiency of protein C, protein S, or antithrombin; resistance to activated protein C; pregnancy or recent childbirth; or oral-contraceptive use) did not materially af fect the risk estimates. Conclusions. High plasma homocysteine levels are a risk factor for deep-vein thrombosis in the general popu lation. (N Engl J Med 1996; 334:759-62.) ©1996, Massachusetts Medical Society.
M ILD hyperhomocysteinemia is an established risk factor for atherosclerosis and vascular disease.1,2 In classic homocystinuria, half the vascular complica tions are of'venous origin,3 but until recently it has been unclear whether mild hyperhomocysteinemia is also a risk factor for venous thrombosis.2,1,3 In a case-control study. Falcon et al. found that hyperhomocysteinemia was a risk factor for thrombosis in people younger than 40 years of age. They reported that the difference in homocystcine levels between case patients and control subjects was particularly evident after methionine load ing (since methionine is a precursor of homocysteine). Recently, we found hyperhomocysteinemia to be a risk factor for recurrent venous thrombosis in patients be tween 20 and 70 years of age, as compared with controls from the general population.7 Although the results of these studies support the hypothesis that mild hyperho mocysteinemia is a risk factor fur venous thrombosis, the studies were not designed to estimate the risk in the general population.
We measured homocysteine concentrations in patients and matched control subjects participating in the Leiden Thrombophilia Study."' 11 This is a population-based case-control study designed to measure the effect of sev eral acquired and genetic risk factors for thrombosis in the general population. Because of the data available on the study subjects, we were able to investigate wheth er the effect of hyperhomocysteinemia was independent of other well-established risk factors for thrombosis, such as a deficiency of protein G, protein S, or antithrombin; use of oral contraceptives; and pregnancy or recent childbirth. Recently, resistance to activated pro tein G caused by a single point mutation in the factor V gene (factor V Leiden) has been reported to be the most common hereditary cause of venous thrombosis.1 " Since hyperhomocysteinemia also appears to be com mon, w7 e examined the risk of thrombosis in persons with both abnormalities.
M e t h o d s
The methods by which blood samples were obtained and interview data were collected have been described elsewhere.*'11 The study pro tocol was approved by the local ethics committee, and all participants gave their informed consent. Briefly, consecutive patients younger than 70 years of age who had a first episode of deep-vein thrombosis, objectively confirmed (by impedance plethysmography, Doppler ul trasonography, compression ultrasonography, or contrast venogra phy), between 19B8 and 1993 and who had no known cancer were se lected from the files of three anticoagulation clinics in the Netherlands (in Leiden, Amsterdam, and Rotterdam). These clinics monitor the anticoagulant treatment of virtually all patients in well-defined geo graphic areas. Each patient was asked to find his or her own healthy control subject of the same sex and age (within five years) by asking neighbors or friends. We restricted the present analysis to case pa tients and controls who were seen at the Leiden Anticoagulation Clin ic and whose blood samples were processed and frozen on site with minimal delay. (Blood samples from participants in Amsterdam and Rotterdam were also processed in Leiden, which caused delays of sev eral hours, and homocysteine measurements were therefore le.ss accu rate than those measured in samples from subjects in Leiden.11)
The total homocvst.cine concentration was measured in ciliated d plasma by automated high-performance liquid chromatography with reverse-phase separation and fluorescent detection (with a Gilson 232-401 sample processor, Spectra-Physics 8800 solvcnt-delivery system, and Spectra-Physics LC 304 fluorometer). We used the method de scribed by Fiskerstrand et al.l:! with some modifications.1'1 If not other wise stated, hyperhomocysteinemia was defined as a homocysteine lev el above the 95th percentile in the control group (18.5/xmol per liter).
We calculated matched odds ratios as estimates of the relative risk of thrombosis for homocysteine values above a given point, with the matching factor taken into account. The univariate matched odds ra tio is the ratio of the number of pairs of case patients and controls in which the homocysteine value for the ease patient was above the spec ified level and the value for the control was below that level to the number of pairs in which the homocysteine value for the control was above the specified level and the value for the case patient w^as below that level. The 95 percent confidence intervals were calculated from 7(i0 TM E NEW ENGLAND JO U R N A L OE M ED ICIN E March 21, 1996 a conditional logistic-regression algorithm by the maximum-likelihood method, with Egret soi l ware. We also investigated a possible dose-response relation by calculating odds ratios for several ranges of homocysteine concentrations in a conditional logistic model. In addi tion, we calculated odds ratios for men and women separately and for several age groups in order to study possible differences in risk among these subgroups. We further explored the differences in risk between men and wom en by taking risk factors specific to women into account -specifical ly, the use of oral contraceptives, pregnancy, and recent childbirth. We analyzed the risk of thrombosis among women less than 50 years old, both with and without the inclusion of women with these risk lactors, by calculating unmatched odds ratios. The use of unmatched odds ratios was necessary because in the restricted groups many matched pairs would not have been complete. Since the matched and unmatched odds ratios did not differ substantiallv in anv oi our analt * yses, we considered this approach justified.
We also assessed whether the increased risk associated with hyperhomocysteinemia in both sexes was confounded by other risk factors, such as a deficiency of protein C, protein S, or antithrombin. We re peated the analysis after excluding subjects with abnormally low lev els of these proteins (measured, as previously reported, with a single lest") and estimated the risk associated with hyperhomocysteinemia in persons with normal protein G, protein S, and antithrombin levels.
Finally, we looked at the possibility of an interaction between hy perhomocysteinemia and heterozygosity (carrier status) for factor V Leiden, a rather common dr ice? that causes resistance to activated protein G. We analyzed this interaction by calculating univariate odds ratios for thrombosis in persons with both or either of these risk fac tors, as compared with persons with neither risk factor.
R esu lts
The ratio of male to female subjects among both the case patients and the controls was 1:1.3, and the mean age was 44 years (range, 16 to 70 For the case patients and 16 to 71 For the controls); both these variables were used in matching the case patients and the controls.
The median plasma homocysteine level in the pa tients was 12.9 /xmol per liter (range, 4.8 to 60.2), and that in the controls was 12.3 /¿mol per liter (range, 6.4 to 37.5). The homocysteine concentrations oF individual case patients and controls are shown in Figure 1 . The 95th percentile oF the homocysteine levels in the control group was 18.5 fimol per liter. OF the 269 pa tients, 28 (10 percent) exceeded this cutoFF, as com pared with 13 (5 percent, by definition) in the control group. The matched odds ratio for deep-vein thrombo sis in .subjects with a homocysteine concentration above the 95th percentile, as compared with those whose ho mocysteine levels were at or below that value, was 2.5 (95 percent confidence interval, 1.2 to 5.2). When the cutoff was set at the 90th pcrcentile, the matched odds ratio was L9 (95 percent confidence interval, 1.1 to 3,3); it was 4.0 (95 percent confidence interval, 1.4 to 12.0) when the cutoff was the 97.5th percentile (Table 1) .
In order to evaluate the possibility oF a close-response relation, we stratified the patients and controls accord ing to their homocysteine concentrations and calculated odds ratios for thrombosis in the patients at the higher levels as compared with those at the lowest level, As Figure 2 shows, the risk of thrombosis did not increase among subjects with homocysteine levels up to 18 /¿mol per liter; the risk was greatly increased above 22 /xmol per liter, however, indicating a threshold effect rather than a continuous dose-response relation.
Odds ratios for several age groups and for men and women separately are shown in Table 2 . For both sexes, there was a sharp increase in the risk of thrombosis as sociated with hyperhomocysteinemia at increasing ag es. The overall odds ratio for thrombosis associated with hyperhomocysteinemia in women was 7.0 (95 percent confidence interval, 1.6 to 30.8), and in men it was 1.4 (95 percent confidence interval, 0.6 to 3.4), with the cutoff set at the 95th percentile of the homocysteine levels in the control group (P = 0.067 for the compari son between the sexes). When we calculated the 95th percentile of the distribution of homocysteine levels for men and women separately, we Found a 95th percentile oF 17.1 jamoi per liter among women and 20.0 /xmol per liter among men in the control group. Using these cut-oFFs For hyperhomocysteinemia, wc found an odds ratio for thrombosis of 3.8 (95 percent confidence interval, 1.4 to 10.2) for women and 1.8 (95 percent confidence interval, 0,6 to 5.4) for men.
The higher rate of hyperhomocysteinemia in wom en than in men was present at all ages, making it un likely that the difference was due to risk factors spe cific to women, such as the use of oral contraceptives, recent childbirth, or pregnancy. Indeed, when we ex cluded women with these risk factors, the unmatched odds ratio for thrombosis that was associated with hy perhomocysteinemia (with the 95th percentile for both sexes -18.5 /¿mol per liter -as the cutoff for hyperhomocysteinemia) among women under the age of 50 was 11.3 (95 percent confidence interval, 2.7 to 46.0), whereas it was 2.8 (95 percent confidence interval, 0.9 to 8.7) for all women, both those with and those with out these risk factors, under the age of 50.
Of the 269 patients, 15 had protein G deficiency, 7 had protein S deficiency, and 10 had antithrombin deficien cy. In the control group, Four had protein C deficiency, ,;I:ur each cutoff point, subjects classiliccl as having hyperliumocysteinemia were those with plasma homocysteine levels above ihe cutoff value, and subjects classilied as not having hyperhomocystcinemia were those with levels at or helow the cutoff value ("below cutoff"). The percentiles used as cutoffs were for the distribution of homocysteine values in the control group, Odds ratios were calculated us the risk of thrombosis in the subjects with hypcrhomocysteinemia as compared with that in the subjects without hypcrhomocysteinemia. Cl denotes confidence interval. eight had protein S deficiency, unci eight had antithrom bin deficiency. Alter excluding these subjects, we found a matched odds ratio for deep-vein thrombosis of 2.6 (95 percent confidence interval, 1.2 to 5.9), as compared with 2.5 (95 percent confidence interval, 1.2 to 5.2) when those subjects were included; this result shows that the cffcct of homocysteine is largely independent of these deficiencies in clotting-factor inhibitors.
With respect to the combination of factor V Leiden and hyperhomoeysteinemia, we calculated odds ratios for thrombosis in subjects with both risk factors or either one in relation to subjects with neither. A total of 47 of the pa tients carried I he factor V Leiden mutation, ¿is compared with 7 of the controls. The small number with both de fects made the results statistically unstable and some what sensitive to the cutoff chosen for elevated homocys teine levels. When the 90th percentile was used as the cutoff, the odds ratio for thrombosis associated with the presence of'both risk factors (factor V Leiden and hyperhomocysteinemia) was (95 percent confidence inter val, 0.7 to 16.9); the odds ratios lor thrombosis associated with factor V Leiden alone and hypcrhomocysteinemia alone, calculated separately, were 9.5 and 2.2, respective ly. With the 95th percentile used as the cutoff, the odds ratio for the combination of risk (actors was 2.0 (95 per cent confidence interval, 0.1 to 10.9), whereas the odds ratios for each risk factor separately remained virtually unchanged. The statistical uncertainty of results based on these data is reflected in the wide confidence inter vals, which do not exclude a relative risk as high as 16.9. D is c u s s io n Our study show's that hyperhomoeysteinemia is a risk factor for deep-vein thrombosis in the general popula tion. Moreover, our results suggest that the association between mild hyperhomoeysteinemia and venous throm bosis is similar in degree to that reported for hyper homo cysteinemia and arterial vascular disease,b,lb An unex pected finding was the substantial increase in the risk of thrombosis at the highest plasma homocysteine levels. Our data suggest that there may be a threshold level above which homocysteine has a thrombogenic effect.
Falcon et al. reported that hyperhomoeysteinemia was a risk factor for juvenile thrombosis.6 Our data imply that hyperhomoeysteinemia is a risk factor for thrombo sis in adult subjects as well, since w;e found an increasing odds ratio with increasing age.
When we analyzed men and women separately, we found a difference in the risk of' thrombosis associated wfith hyperhomoeysteinemia. Even when we used differ ent cutoff points for hyperhomoeysteinemia in men and women by calculating the 95th percentiles of their ho mocysteine distributions in the control group separate ly, we found that the odds ratio was roughly twice as high for women as for men. This .suggests that women may be more susceptible to the pathologic effects of el evated homocysteine levels, even though their homocys teine levels are in general lower than those of men.1 This effect cannot be explained by risk factors specific to women (such as pregnancy, recent childbirth, and oralcontraceptive use); an effect of these risk factors was unlikely in any case because the difference between men and women who did not have such risk factors was even more pronounced.
Hyperhomoeysteinemia remained a risk factor for iT he odds ratio was 12.0 (95 percent confidence interval, l.fi to 92.3) when the cutoff used was the 90tlt percentile in the control group.
deep-vein thrombosis after we excluded subjects with other well-established risk factors; that is, the associa tion with thrombosis was not explained by the presence of other hereditary risk factors for thrombosis, such as a deficiency of protein C, protein S, or antithrombin. The same was true of the most common hereditary risk fac tor for deep venous thrombosis, resistance to activated protein C, since hyperhomocysteinemia also increased the risk of thrombosis in those without this abnormal ity. We investigated a possible interaction between re sistance to activated protein C (factor V Leiden) and hy perhomocysteinemia. Although we found that the risk of thrombosis may be higher in carriers of the mutation who have hyperhomocysteinemia than in noncarriers with hyperhomocysteinemia, the combined effect in our subjects seemed smaller than for factor V Leiden alone. Because of the small numbers involved, the only rea sonable conclusion is that the two factors do not poten tiate each other.
Many hypotheses have been proposed to explain how hyperhomocysteinemia may lead to venous thrombosis and atherosclerosis. One hypothesis is that homocystcinc has a toxic effect on the vascular endothelium and on the clotting cascade,1,2 Several in vitro studies seem to support this view.17,18 However, virtually all these stud ies used amounts of homocysteine that produced higher-than-physiologie concentrations. Alternatively, hy perhomocysteinemia may reflect abnormal methionine metabolism that affects the methylation of DNA and cell membranes.19
Elevated homocysteine levels may result from low lev els of folic acid, vitamin B,-, or vitamin B)2. Moreover, sev eral genetic alterations in enzymes involved in homocys teine metabolism have been described.20'22 It remains unclear whether hyperhomocysteinemia of different caus es entails the same risk of thrombosis. Nevertheless, it is well known that vitamin supplementation lowers ho mocysteine concentrations in almost all subjects with hy perhomocysteinemia, regardless of the underlying cause.
We conclude that mild hyperhomocysteinemia is a risk factor for deep-vein thrombosis in the general pop ulation. The next question to be answered is whether homocysteine-lowering therapy -folic acid, vitamin 
